<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302510</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0608</org_study_id>
    <nct_id>NCT00302510</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy</brief_title>
  <official_title>Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of immunoadsorption in the
      treatment of lipoprotein glomerulopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lipoprotein glomerulopathy is characterized by nephritic syndrome glomerular protein thrombi
      and lipid abnormalities, particularly with an elevated level of plasma apoprotein E
      (apoE).There are no efficiency way to treat lipoprotein glomerulopathy. We firstly
      successfully treat 2 patients by protein A immunoadsorption with remarkable decreased urine
      protein and reduction of lipoprotein thrombi on repeated renal biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">March 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of immunoadsorption in the treatment of lipoprotein glomerulopathy.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of immunoadsorption in the treatment of lipoprotein glomerulopathy.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>immunoadsorption</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunoadsorption</intervention_name>
    <description>immunoadsorption</description>
    <arm_group_label>immunoadsorption</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A new diagnosis of lipoprotein glomerulopathy proved by histology and serology

          2. Age 15~60 years, sex free

        Exclusion Criteria:

          1. Serum creatinine &gt; 500 umol/l

          2. Severe viral infection(HBV, HCV, CMV) within 3 months of first randomization or known
             HIV infection

          3. Congenital or acquired immunodeficiency

          4. Patients with severe infection or central nervous system symptoms

          5. Immediately life-threatening organ manifestations (e.g. lung haemorrhage or massive
             gastro-intestinal bleeding, heart failure due to pericarditis or myocarditis, liver
             dysfunction measured on at least 2 separate occasion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-hong Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2006</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name_title>
    <organization>Nanjing University School of Medicine</organization>
  </responsible_party>
  <keyword>lipoprotein glomerulopathy</keyword>
  <keyword>treatment</keyword>
  <keyword>immunoadsorption</keyword>
  <keyword>apolipoprotein E</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

